We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

A drug problem

22 February 2016 By Robyn Mak

A unit of the Chinese e-commerce giant has suffered a run-in with mainland regulators. Though shares in Hong Kong-listed Ali Health soared when Alibaba invested last year, reality has proved less exciting. It’s a reminder that even Jack Ma can’t cure investors’ loss of faith.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)